Martin Fassnacht

Martin Fassnacht, MD is Professor of Medicine and Head of the Division of Endocrinology and Diabetes at University Hospital Würzburg, Germany, where he leads the largest clinical and research program in adrenocortical carcinoma (ACC) in Europe. He is widely regarded as the world's foremost clinical expert in ACC, with landmark contributions to the evidence base for mitotane-based therapy, systemic chemotherapy, and emerging immunotherapy strategies for this rare and aggressive malignancy. Professor Fassnacht was the principal investigator of FIRM-ACT, the first randomized phase III trial in ACC, which established etoposide, doxorubicin, cisplatin, and mitotane (EDP-M) as the standard first-line chemotherapy regimen for advanced ACC. Published in the New England Journal of Medicine in 2012, FIRM-ACT provided the first robust evidence base for systemic therapy in this disease. He has also led the ADIUVO and ADIUVO-2 trials investigating adjuvant mitotane and immunotherapy in resected ACC, and has contributed pivotal studies on the molecular pathogenesis and biomarker landscape of ACC including Wnt/β-catenin pathway alterations and steroid hormone profiles. Beyond ACC, Professor Fassnacht contributes to the management of pheochromocytoma and paraganglioma and leads the European Network for the Study of Adrenal Tumours (ENSAT). He chairs the European Society of Endocrinology Clinical Practice Guideline on ACC and has authored over 250 peer-reviewed publications in endocrine oncology.